Yüklüyor......
Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
Chimeric antigen receptor (CAR) modified T cell therapy has revolutionized the treatment of relapsed and refractory hematological malignancies. Through targeting of the CD19 antigen on B cells durable remissions have been achieved in patients with B cell non-Hodgkin lymphoma and acute lymphoblastic...
Kaydedildi:
| Yayımlandı: | Front Oncol |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6423158/ https://ncbi.nlm.nih.gov/pubmed/30915277 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00146 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|